# Neopenda

Life-saving technology for the world's most vulnerable newborns

- Canonical URL: https://wefunder.com/neopenda
- Entity ID: wefunder:company:172428
- Last updated: 2026-06-09T05:01:10Z
- Generated at: 2026-06-10T03:03:34Z

## Quick facts
- 150,000+ monitoring hours across 50+ hospitals, 5,000+ newborns no longer left unseen
- 53% YoY sales growth in Kenya
- $6M+ from Fortune 500s, global health foundations, and top accelerators including Techstars
- Patented, CE-marked, ISO 13485 certified, a validated commercial product
- Built by Columbia-trained biomedical engineers with Medtronic, GSK, and Eli Lilly team experience
- Qualified by WHO andUNITAID as a breakthrough technology for low-resource settings

## Active fundraises
- wefunder:fundraise:132318: 4(a)(6) successful (USD)
- wefunder:fundraise:132317: 4(a)(6) successful (USD)

## Story
Every year, 2.3 million newborns die from causes we already know how to treat. It's not clinical failure. It's infrastructure failure.Neopenda is a commercial medical device company at the turning point between early traction and scale.We build vital signs monitoring technology for hospitals that operate with too few nurses, too many patients, and too little margin for error, starting with newborns in Africa.The hardest risks are behind us. The biggest value creation is ahead.Every day, patients die from causes that are preventable and treatable, not because clinicians don't know what to do, but because deterioration happens silently between checks.In top U.S. hospitals, a nurse cares for 2 patients at a time. In many emerging markets, that ratio is 20-to-1 or worse. Clinical research shows that adding just one extra patient per nurse increases mortality by 16%.When you're the only nurse in a crowded ward surrounded by fragile lives, you can't catch what you can't see. Patients deteriorate silently, care becomes reactive, and lives are lost, not because treatment doesn't exist, but because visibility does.Now imagine you are that nurse. It's the middle of the night, the ward is full, and you have no equipment to tell you who needs you most. Somewhere in that room, a baby's oxygen is dropping. By the time you notice, the window for intervention may have passed.This is the reality for millions of hospitalized newborns. Not a failure of medicine, a failure of infrastructure.neoGuard is a vital signs monitoring system purpose-built for real-world hospitals, giving clinicians the three scarcest resources in healthcare: visibility, prioritization, and time.Medical-grade wearable monitors track pulse rate, oxygen saturation, respiratory rate, and temperature.Data streams wirelessly to a centralized dashboard, giving one nurse visibility across an entire ward.Built-in localization helps staff find the right patient instantly.In healthcare, minutes matter. neoGuard turns blind spots into action, and reactive care into proactive intervention.Most patient monitors weren't built for real-world hospitals. They assume stable power, low patient density, and constant maintenance, and in many emerging markets, that's exactly why they end up abandoned, broken, or locked away in equipment graveyards.We didn't retrofit Western hospital equipment. We started from scratch, spending years on the ground across dozens of hospitals, working alongside 1,000+ clinicians to design for the environments that need it most:Built-in battery life to withstand frequent power outagesDurable and cleanable for overcrowded, high-turnover wardsAffordable and scalable for facilities with limited budgetsThe result is a system that is durable, intuitive, and affordable, and actually gets used.neoGuard is no longer an experiment or a pilot, it's a commercially deployed, regulated medical device trusted in clinical settings across multiple countries.CE Mark (Class IIb, EU), PPB clearance (Kenya), and TMDA clearance (Tanzania)ISO 13485 certified quality management systemPatented in the U.S., Japan, and KenyaQualified by the WHO and UNITAID as an innovative technology for low-resource settingsThe regulatory heavy lifting is done. What remains is scale.e've moved decisively beyond early experimentation. neoGuard is now embedded in routine hospital care, delivering continuous monitoring at scale:5,000+ patients monitored500+ devices sold across 40+ customer facilities150,000+ hours of monitoring logged53% year-over-year revenue growth in Kenya433% YoY growth in monitoring hoursHospitals aren't evaluating neoGuard, they're using it.Neopenda's growth strategy is built on a simple truth: in healthcare, trust travels. We enter hospitals through neonatal wards, the highest acuity, highest scrutiny environment, and let clinical outcomes do the selling.From there, adoption expands ward by ward within facilities, spreads organically through peer referrals between hospitals, and ultimately converts into institutional procurement at the government and NGO level.This model converts clinical trust into repeatable revenue, creating a durable growth engine built to scale across health systems, not just single facilities. This isn't theory, here's what embedded adoption looks like in practice:558 clinicians trained across multi-country operations, and counting.94% of users report neoGuard as their primary tool for reducing manual monitoring.81% of clinicians demand permanent integration into hospital processes.100% real-time clinical data captured across every deployment.Hospital administrators aren't moved by mission statements, they're accountable to budgets, staff capacity, and patient outcomes. neoGuard earns its place because it solves real operational problems:Clinicians can prioritize the sickest patients without relying on instinct aloneMissed deterioration events are reduced before they become emergenciesStaff workload decreases without adding new burden or training overheadThe result is a device that doesn't just get purchased, it gets used, trusted, and eventually demanded. Once installed, neoGuard becomes essential infrastructure.Starting with newborns was a deliberate strategic choice. Neonatal care carries the highest clinical risk, the strictest regulatory requirements, and the lowest tolerance for failure. By succeeding here first, we cleared the hardest hurdles upfront, and proved that we can execute in the most demanding clinical environments on earth.That foundation now unlocks something much larger. We are defining a new category of continuous patient monitoring built for environments where reliability, simplicity, and uptime matter more than feature density, and the same infrastructure that monitors newborns today is the platform that scales across pediatrics, maternity, and general wards tomorrow.Monitoring is the entry point. Stronger systems are the outcome.We start with the hardest problem, and expand outward into a global platform.Today we are selling into a $188M market for in-patient neonatal monitoring in Sub-Saharan Africa, where 70% of hospitals still have no continuous monitoring solution.From there, our expansion path is clear: a $5.7B near-term market for neonatal and pediatric monitoring across global emerging markets, and a $35.8B long-term platform opportunity in patient monitoring across all ages and care settings worldwide.We entered through the hardest door. The rest opens from here.neoGuard doesn't just monitor patients, it captures continuous, high-fidelity clinical data that no one in these settings has ever had access to before. Over time, that data layer becomes something far more powerful than a monitoring device:Earlier detection of deterioration before it becomes a crisisSmarter prioritization of clinical resources across entire wardsSystem-level visibility that helps health systems anticipate risk and intervene soonerThis is the platform opportunity. From a single device at the bedside to an intelligence layer across entire health systems, from saving individual lives to strengthening the infrastructure that protects all of them.Neopenda's team spans Kenya, Nigeria, the United States, and Argentina, because building technology that works in the real world requires people who understand it firsthand.Our biomedical engineers, pharma executives, and market builders bring careers shaped by Medtronic, GlaxoSmithKline, Eli Lilly, and Columbia University, combined with thousands of hours on the ground in the hospitals we serve.We don't just understand the problem from the outside. We live and work in the communities where neoGuard is deployed.The medtech market is demonstrating strong appetite for validated clinical technology at scale. Recent IPOs including Ceribell (CBLL) and Kestra (KMTS) illustrate viable public market pathways for companies in our space, while investors in pediatric and wearable health technology, such as those backing Kiddo Health, are transacting at high multiples.Strategic acquirers including large medtech players and global health-focused funds have a consistent track record of acquiring proven emerging market health infrastructure. Neopenda is committed to delivering returns for its investors and is building toward multiple viable exit pathways.Most startups ask you to invest in possibility. Neopenda offers momentum.The technical risk is gone, neoGuard is patented, regulated, and deployed in real hospitals. The market risk is shrinking fast, sales are growing, adoption is repeatable, and expansion is underway. Capital now accelerates revenue, not R&D.And the platform upside is just beginning. Early investors participate before recurring revenue and data economics are fully priced in.But this round is about more than returns. Where you live shouldn't determine whether you live, and we're inviting our community of clinicians, parents, supporters, and everyday investors to be part of changing that. By investing in Neopenda, you're backing a proven product, a growing business, a massive underserved market, and a team already executing on the ground.We're entering the phase where every dollar works harder. We'd love for you to be part of what comes next.This community round is a strategic component of our broader raise.Its role is to pull forward the commercial milestones that convert demand into repeatable revenue, laying the foundation for company-level profitability.The medtech market is demonstrating strong appetite for validated clinical technology at scale. Recent IPOs including Ceribell (CBLL) and Kestra (KMTS) illustrate viable public market pathways for companies in our space, while investors in pediatric and wearable health technology, such as those backing Kiddo Health, are transacting at high multiples. Strategic acquirers including large medtech players and global health-focused funds have a consistent track record of acquiring proven emerging market health infrastructure. Neopenda is committed to delivering returns for its investors and is building toward multiple viable exit pathways.

## FAQ
1. **Is your target market limited to Africa for the time being? Will the majority of your employees eventually be people living in Africa, including managers? Do you have many competitors or potential competitors?**
   - Thanks for the thoughtful question! Our current focus is on Africa as it’s one of the largest untapped markets for healthcare innovation with a global neonatal mortality burden and a critical shortage of clinical tools. That said, the challenges we’re solving exist in 85% of emerging markets globally, and we’ve already begun piloting in other strategic countries beyond Africa. As we grow, our hiring philosophy is simple, hire first in Africa unless there’s a specific reason not to, such as ti...
2. **Hi Sona, are you looking out for app development team to build out the app**
   - Hi Majed, thanks for your question! We have an in-house team that has built out our existing android app, and will continue to build out future apps.
3. **Hey, How can I reach the founder to discuss company regarding investing?**
   - Hi Yaacov- happy to chat. Feel free to email me at sona@neopenda.com.
4. **1) How will you make money ? 2) Is a working piece deployed ? 3) Any revenue info and cost per unit info ?**
   - Thanks for your question! We sell neoGuard in packages of 5–15 devices to public and private hospitals, as well as through channel partners such as county governments, Ministries of Health, NGOs, and distributors. To date, we've deployed over 400 devices across 45+ facilities, with 40%+ margins on each package sold and a clear path to expand to 70% margins through local production on the African continent.
5. **Hello 1 vital signs monitoring is not really a strong IP. Can be easily copied w existing sensors. 2 The money is in the US market and you are totally absent. 3 This started in 2016 now nearly 10 years later you are still on the runway. My investment most likely will never see...**
   - We appreciate your perspective and the opportunity to clarify a few important points. First, our vital signs monitor, neoGuard, is protected by patents in the US and several other countries, covering the unique design and application of our technology in low-resource settings. While the underlying sensors may be available, our innovation lies in how we’ve integrated them into a clinically validated, low-power, modular solution tailored for environments where traditional monitors fail. That’s ...

## Team
- Sona Shah ( CEO & Co-founder)
- Teresa Cauvel (CTO & Co-founder)
- Washington Dinga (Sales Manager)
- Ryan Cavanaugh ( Supply Chain Lead )
- Diana Byegon (Customer Success Manager)

## Q&A
- Q: Hello 1 vital signs monitoring is not really a strong IP. Can be easily copied w existing sensors. 2 The money is in the US market and you are totally absent. 3 This started in 2016 now nearly 10 years later you are still on the runway. My investment most likely will never see daylight.
  - A: We appreciate your perspective and the opportunity to clarify a few important points. First, our vital signs monitor, neoGuard, is protected by patents in the US and several other countries, covering the unique design and application of our technology in low-resource settings. While the underlying sensors may be available, our innovation lies in how we’ve integrated them into a clinically validated, low-power, modular solution tailored for environments where traditional monitors fail. That’s what makes our IP strong and defensible. Beyond product IP, we’ve built significant market IP—deep partnerships with governments, regulatory approvals, trained clinical networks, and distribution channels across East and West Africa. These are major barriers to entry and key drivers of long-term value that can’t simply be copied. While the US market is important, we’re focused on a vastly underserved global opportunity: 85% of the world still lacks access to basic vital signs monitoring. In Africa alone, there’s a $3.4B+ addressable market—and we’re already deployed in over 50 hospitals. US expansion is on our roadmap, likely through licensing, but our near-term focus remains where the need and impact are greatest. Finally, it’s worth noting that medical device companies—especially those addressing systemic global health gaps—take time. We’ve gone from concept to regulatory approval to commercial traction in a complex sector, and today we’re growing rapidly with a validated product and a scalable business model. And importantly, yes—we expect returns for our investors. Financial returns, absolutely—but also meaningful returns in the form of improved patient outcomes and expanded access to care. Delivering both is core to our model and always has been. We’re proud of the path we’ve taken—and even prouder of what’s ahead.
- Q: first, I love watching sona speak she is amazing! please more interviews with her! I invested in 2 companies centered around babies, therefore, this caught my eye. I like the product with the dashboard more than the other one. I have several questions, your financials scare me at least from what I can see which is 2024. 1. how did you numbers turnout for 2025? 2. from looking at what you have, your cogs is 92 percent of your revenue, which is not good. the second highest I have ever seen compared to revenue and I have over 150 companies in my portfolio. did you made any progress regarding that? 3. as I look at your sales and marketing expense. your revenue should be at least 4, 5 times that. did you make any strides there? 4.your professional fees is almost 3 times your revenue, did you improve that? 5. your general and admin fees is more than your total revenue. making any strides there. hate for you to have an amazing product yet never make a profit or if you do you barely make anything. which would be not good for your investors. 6. outside of the obvious more customers. what do you think would stop you from getting to a revenue of 50 million etc in 5 years. no disrespect but 14 million in a category you are doing is a drop in the bucket. do you think that focusing so much on Kenya and surrounding countries the reason why your numbers are where they are? in the us alone you should be able to do 14 million at least annually. being a veteran I spent a lot of time in Africa and the middle east. 7. is your product covered by any insurances if not what would the cost be of both products? 8. where you produce the product what is your max capacity? 9. what is your moat? thanks for your time!
  - A: Hi John, thanks so much for the thoughtful questions — and I completely agree with the underlying concern that a great product must translate into a profitable, scalable business. A lot of what you’re reacting to in the 2024 financials reflects a deliberate 2023 pivot from a distributor-led model to direct sales, which temporarily inflated COGS, sales & marketing, G&A, and professional fees before revenue starts to catch up. Now, that picture looks very different: gross margins are now ~50%, operating costs have come down materially, and we’re on a clear path to operational profitability in Kenya by mid-year driven by both government contracts and improved unit economics. We don’t have manufacturing capacity constraints, reimbursement in our current markets is largely non-insurance based, and our moat is driven by deep workflow integration — clinician training, permanent embedding into hospital processes, and real-time clinical data as a byproduct — which makes neoGuard infrastructure, not a swappable device. I’d love to walk you through updated numbers and the 5-year path to scale live if helpful — feel free to reach out directly at sona@neopenda.com
- Q: Something you should explore. This might be something, or made into something that the military could use. Something that could be easily applied to people injured in combat. Or something first responders like police could use. To help monitor someone until ems comes.
  - A: Great point — thanks for flagging that! Because neoGuard is built for the harshest, lowest-resource environments, the platform adapts well to other high-acuity, high-mobility settings. We’re actively exploring applications for military medicine, disaster response, and remote patient monitoring in particular, but see many additional opportunities for expansion. Happy to share more about our growth strategy and any clinical or operational data on request.
- Q: 1) How will you make money ? 2) Is a working piece deployed ? 3) Any revenue info and cost per unit info ?
  - A: Thanks for your question! We sell neoGuard in packages of 5–15 devices to public and private hospitals, as well as through channel partners such as county governments, Ministries of Health, NGOs, and distributors. To date, we've deployed over 400 devices across 45+ facilities, with 40%+ margins on each package sold and a clear path to expand to 70% margins through local production on the African continent.
- Q: I signed up to chat with you Friday sona, good stuff! I was looking at a question you got last year. a very important one that you didn't answer you spoke about the margins but didn't answer the question. the question was what was the cost per unit. one of your advantages you have is low cost, yet you don't say anything about the cost.
- Q: I still have not invested because I am struggling to understand any “big picture” trend. Specifically, is the plan to first set up something in Kenya, then try to “scale up” in Kenya, and then try to “scale up” outward (to where? other African countries or globally or any particular geographical market)? If so, what are the approximate timelines?
  - A: Great question—our strategy is to prove, systematize, and then scale, both geographically and through product expansion. We start in core markets like Kenya, where we’ve validated our ability to sell across multiple channels (facilities, NGOs, governments). From there, we expand into new markets using tailored approaches based on three country profiles: - Direct + institutional sales (like Kenya) - Primarily NGO/government-led markets - Distributor-led markets In parallel, we are expanding our product footprint, both by extending neoGuard into new use cases (e.g., beyond newborn care into broader patient populations and care settings) and by developing neoIntel, our data platform, which is designed to add a recurring revenue layer over time. The key is that we are building repeatable playbooks across both markets and products, so growth is not dependent on any single geography or offering. In terms of sequencing, we are focused on deepening traction in existing markets while selectively expanding into new ones where we have early footholds, and layering in new products as we scale.
- Q: 1)Do you make money only from selling the physical device or there is a saas or etc that gives annual recurring revenue? If there's so what part of the revenue is annual recurring revenue in percentages? 2) what is the costs of scale? (Want to assess probability of this) Note: this is very important point to mention due to the fact that most of the company future success derived from the scale. 3)in how many years do you predict will be the exit(in case will be)?
  - A: Thanks for the thoughtful questions, Etai. 1) Today, our revenue is primarily from device sales (capital expenditure). However, we are actively building our data intelligence platform (neoIntel), which is designed to introduce a recurring revenue stream through software, analytics, and service layers. This platform is expected to launch around 2027. While recurring revenue is not yet a meaningful portion of revenue today, we are intentionally evolving toward a hybrid model where software and data services represent an increasing share of revenue over time. 2) Our model is designed to scale efficiently by leveraging what we’ve already built—regulatory approvals, distribution channels, and a validated product. Key cost drivers of scale include: - Manufacturing & supply chain: Unit costs decrease with volume, improving margins as we scale. - Market expansion: Regulatory, distribution, and in-country sales investments for new geographies. - Commercial team & partnerships: Expanding sales and customer success to drive utilization and retention. - Product development: Continued investment in new products and our software platform. Importantly, we’ve already demonstrated the ability to sell across multiple channels (direct facilities, NGOs, governments), which reduces risk and allows us to scale through repeatable playbooks rather than starting from scratch in each new market. 3) We cannot guarantee a specific exit timeline. That said, in medtech, exits typically occur once companies reach meaningful clinical validation, regulatory traction, and commercial scale. Our focus over the next several years is to continue scaling revenue, expanding geographically, and building out our product and data platform—positioning the company for a potential exit in the medium to long term.
- Q: What is the exit plan (acquisition, IPO, merger, etc.) in which investors will be able to see a ROI?
  - A: Thanks for your question! We are building Neopenda to be a highly scalable, clinically validated health technology platform—one that is attractive to both strategic and financial acquirers. In medtech, the most common exit pathway is acquisition by a larger medical device or healthcare company. Strategic buyers consistently acquire companies that have demonstrated strong clinical impact, regulatory traction, and commercial scale—particularly in areas like wearable monitoring and data-driven healthcare. Given our focus on critical gaps in emerging market health systems and our growing footprint across multiple countries, we believe Neopenda could be a compelling acquisition target for global medtech companies, digital health platforms, or healthcare-focused funds. While acquisition is the most likely path, we are intentionally building the company to support multiple exit options over time. We cannot guarantee a specific exit or timeline, but our focus is on building a valuable, durable company that can deliver strong returns for investors.
- Q: I will reach out to you again tonight sona! do you chat on weekends, usually when I talk to founders. with my NFL friends now making investments, they have none lol. I am just realizing that this doesn't have to be used for just babies. I invested in a bunch of clinics so this potentially could be a good fit especially your newer product. I see somebody mentioned military application which is a great idea. do you or will you have something where it doesn't have to be on somebody's head? I know being a vet and spending most of my time in war we had on helmets. this doesn't seem like it would fit with a military helmet or won't be very comfortable. already not really that comfortable. if we invest this would have to be a 100 million dollar etc a year company not 14 million in 5 years with a potential 100 million dollar valuation. we need more like a close to or billion dollar valuation company. tbh I don't see how you will be a 75 million dollar a year business going the route you are. thanks for your time. look forward to connecting! have a good day and thank you for your time!
- Q: I reached out to you haven't gotten a response sona. thank you for your time and have a good day
  - A: Hi John, happy to connect! Feel free to email at sona@neopenda.com.
- Q: Hi Sona, Back at the beginning of the raise you mentioned that you were planning to move final assembly to Kenya to improve margins. How are things going on that front?
  - A: Hi Drake, thanks for the question! Things are moving well on that front — we’re headed to Kenya next month to engage directly with potential manufacturing and supply chain partners as part of our plan to localize final assembly and packaging. The goal is to reduce landed costs, improve margins, and shorten lead times while maintaining quality and regulatory compliance. We’ve already validated that our current manufacturing setup can support this transition without capacity constraints, and we’re now in the diligence and partner-selection phase. Happy to share more detail as things progress.
- Q: hey sona I see where you mentioned that you would be happy to share growth strategy and clinical operational data in response to someone's question. I would love to know more about those things!
  - A: Happy to connect- sona@neopenda.com
- Q: I like the newer product more.
- Q: Could you share more details regarding the Vodafone/Cisco funding, Patent Status (pending or granted) and endorsement from WHO/UNITAID (What specifically have they endorsed or funded - the device in particular or the need)
  - A: Thanks for your questions! Vodafone and Cisco provided ~$400K in non-dilutive capital to Neopenda in our early days through competitive global prize competitions (including the Cisco CSR Internet of Everything Innovation Challenge and Vodafone’s Americas Foundation Wireless Innovation Project), supporting early product development and validation of neoGuard Neopenda holds granted patents for neoGuard in the United States, Japan, and Kenya, securing core IP protection in both high-income and priority markets. The recognition from WHO and UNITAID is for neoGuard itself, validating it as a solution for a critical global health need. The WHO featured neoGuard in its 2024 Compendium of Innovative Health Technologies for Low-Resource Settings, recognizing it as a commercially available, clinically validated patient monitoring system designed for use where power and infrastructure are limited (https://www.who.int/publications/i/item/9789240095212) . UNITAID included neoGuard in its 2024 Medical Oxygen Innovation Landscape as a key patient monitoring technology that measures vitals and is designed specifically for under-resourced settings, underscoring the device’s relevance to oxygen management and broader critical care challenges (https://unitaid.org/uploads/The-Medical-Oxygen-Innovation-Landscape.pdf)
- Q: Is this FDA approved? Are there plans to use this in the United States? I understand it was developed in and is being utilized primarily in Kenya.
  - A: Thanks for your question. While our device is not FDA approved, we do hold a CE Mark (the European equivalent of FDA clearance), which is granted by a stringent regulatory authority and aligns with international standards, including those required for FDA clearance. We also operate under ISO 13485 quality management standards. Our primary focus is on the 85% of the world that currently lacks access to medical technologies, though we are exploring licensing opportunities to address unmet needs in the U.S.